Non-surgical ablation for breast cancer: an emerging therapeutic option

Lancet Oncol. 2024 Mar;25(3):e114-e125. doi: 10.1016/S1470-2045(23)00615-0.

Abstract

Non-surgical ablation is emerging as an alternative local therapy option for patients with early-stage breast cancer and encompasses two main types of percutaneous therapeutic procedures: radiofrequency ablation and cryoablation. Both techniques involve obliteration of a spherical lesion and feasibility studies have shown that complete tumour ablation is achievable with good or excellent cosmetic results. Although few clinical studies have directly compared non-surgical ablation with conventional surgical resection, observational studies indicate that clinical outcomes are favourable with acceptable rates of local control and no detriment to long-term survival. There remain outstanding issues with these percutaneous ablative techniques that require resolution before they could be incorporated into routine clinical practice. Hence, a consensus meeting was convened to discuss the challenges of non-surgical ablation and clarify indications for its use alongside clinical management pathways. In this Policy Review we will address some of the broader biological aspects of non-surgical ablation, including immune-modulatory effects and potential novel applications for the future.

Publication types

  • Review

MeSH terms

  • Breast Neoplasms* / surgery
  • Catheter Ablation*
  • Consensus
  • Critical Pathways
  • Female
  • Humans